menu Menu
  • WORLDWIDE
  • CONTACT US
  • About Us
    close
    • About Us
    • Corporate Responsibility
    • Contributions and Donations
    • How We Operate
    • Leadership
    • Our History
    • Featured Stories
  • Research
    close
    • Research
    • Our Research Process
    • Pipeline
    • Clinical Trials
    • Invent with Us
  • Products
    close
    • Vaccines
    • Prescription Products
    • Animal Health
  • Newsroom
    close
    • Latest News
    • Corporate News
    • Product News
    • Research and Development News
    • Company Statements
    • Social Media
  • Careers
    close
    • Careers
    • Why Merck?
    • Apply Now
  • About Us navigate_next
    • Corporate Responsibility
    • How we operate
    • Leadership
    • Our History
    • Featured Stories
  • Research navigate_next
    • Research
    • Our Research Process
    • Pipeline
    • Clinical Trials
    • Invent with Us
  • Product navigate_next
    • Vaccines
    • Prescription Products
    • Animal Health
  • Newsroom navigate_next
    • Latest News
    • Corporate News
    • Product News
    • Research and Development News
    • Social Media
  • Careers navigate_next
    • Careers
    • Apply Now
    • Why Merck?
  • Contact Us

Merck Biosimilars
is at your side at every step.

Learn more

 
 

Health Canada Approves Merck’s STROMECTOL™ (Ivermectin) for the Treatment of Intestinal Strongyloidiasis and Onchocerciasis

Learn more

 
 

RENFLEXISTM (infliximab for injection) Now Added to British Columbia’s Provincial Drug Plan

Learn more

 
 

We have always been and always will be inventing, and we do it for the single greatest purpose: life.

Learn more

 
 

The Merck Patients First Award recognizes excellence and innovation in patient-centred care

Learn more

 
 

Check out our latest news

Learn more

 
 

Voluntary Disclosure of Payments to Healthcare Professionals and Healthcare Organizations

Learn more

 
 

LATEST NEWS
CONNECT WITH US ON SOCIAL
OTHER MERCK SITES
 

Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in life sciences
November 19, 2018

Important Information on MARVELON® 28 (Desogestrel/Ethinyl Estradiol) Oral Contraceptive Tablets – Absence of Day-of-the-Week Label Stickers
September 11, 2018

Health Canada Approves Merck’s STROMECTOL™ (Ivermectin) for the Treatment of Intestinal Strongyloidiasis and Onchocerciasis
September 11, 2018

RENFLEXISTM (infliximab for injection) Added to British Columbia’s Provincial Drug Plan for all Approved Indications
August 22, 2018

Real-World Study of Zepatier® (Elbasvir and Grazoprevir) Demondtrates High Rates of Sustained Virologic Response in a Broad Range of Patients With Chronic Hepatitis C Infection Across Canada
April 12, 2018

Major Funding Expected in Support of Alberta's Life Sciences' Sector
June 20, 2017

Indigenous Researchers Receive $2.6 Million Funding From Merck Canada Inc. for Indigenous Maternal and Child Health Program in Ontario
May 25, 2017

Recent Floods: Alert for Merck Canada Inc. Employees
May 8, 2017

Merck Applauds World Health Organization’s (WHO) World Immunization Week​​
April 21, 2017

SEE ALL LATEST NEWS
 
 
 
 
  • OTHER MERCK SITES
    Merck Patients First Awards
  • Merck for Mothers
  • Merck Manuals
  • Merck.com
  • Investors
 
 
 

Copyright © 2018 Merck Canada Inc. All rights reserved.

  • Privacy
  • Terms of use

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

  • Social media guidelines
  • Terms and conditions for sales
Image: Circle Close Icon

You are now leaving the Merck.ca site, a website maintained by Merck Canada Inc.

The link is provided for your convenience only. Merck Canada Inc. takes no responsibility for the content of any website maintained by any third party and makes no representation as to the accuracy or completeness of any information available through this or any subsequent link.

OKCancel

Forward-Looking Statement ×
 

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.